BioVersys AG

BioVersys AG is a clinical-stage biopharmaceutical company headquartered in Basel, Switzerland, specializing in the research and development of small molecules with novel mechanisms of action to combat antimicrobial resistance (AMR). The company targets serious life-threatening infections caused by multi-drug resistant (MDR) bacteria, including nosocomial infections from Acinetobacter baumannii and Staphylococcus aureus, as well as tuberculosis and non-tuberculous mycobacterial (NTM) infections. Its pipeline features lead candidates like BV100, a novel mode-of-action therapy in Phase 2 for Acinetobacter baumannii hospital infections; BV200, an anti-virulence agent against S. aureus; BV500 series for NTM; and Alpibectir (formerly BVL-GSK098), in Phase 2a collaboration with GlaxoSmithKline for tuberculosis. Leveraging proprietary platforms such as TRIC and Ansamycin Chemistry, BioVersys develops potentiators that restore antibiotic efficacy, inhibit virulence, and address unmet needs in AMR and microbiome modulation. With around 29 employees, it plays a vital role in the biotechnology sector by advancing innovative treatments against high-priority pathogens prioritized by the WHO and CDC.